Bach-Yen Nguyen

TL;DR: In this article, the efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear.

TL;DR: In HIV-infected patients with limited treatment options, raltegravir plus optimization background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks.

TL;DR: Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in patients infected with HCV genotype 1 and stage 4-5 chronic kidney disease.

TL;DR: Raltegravir is a well tolerated alternative to efavirenz as part of a combination regimen against HIV-1 in treatment-naive patients and has rapid and potent antiretroviral activity, which was non-inferior to that of efvirenz at week 48.

TL;DR: When combined with an optimized background regimen in both studies, a consistently favorable treatment effect of raltegravir over placebo was shown in clinically relevant subgroups of patients, including those with baseline characteristics that typically predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low CD4 cell count, and low genotypic or phenotypic sensitivity score.